Akari Therapeutics (NASDAQ:AKTX) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $1.60 price objective on the biopharmaceutical company’s stock.

AKTX has been the topic of several other research reports. Wall Street Zen began coverage on Akari Therapeutics in a research report on Wednesday, May 21st. They issued a “sell” rating on the stock. Maxim Group initiated coverage on Akari Therapeutics in a report on Friday, July 18th. They issued a “buy” rating and a $5.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Akari Therapeutics has a consensus rating of “Buy” and an average price target of $3.30.

Akari Therapeutics Price Performance

Akari Therapeutics stock opened at $0.84 on Tuesday. Akari Therapeutics has a twelve month low of $0.57 and a twelve month high of $3.85. The company’s 50-day moving average price is $1.00 and its two-hundred day moving average price is $1.14.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.